Axsome Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 545
- Market Cap
- $4.2B
- Website
- http://www.axsome.com
- Introduction
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and ...
Open-Label Safety Study of AXS-05 in Subjects With Depression
- Conditions
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 876
- Registration Number
- NCT04039022
- Locations
- 🇺🇸
Clinical Research Site, Everett, Washington, United States
A Trial of AXS-05 in Patients With Major Depressive Disorder
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 327
- Registration Number
- NCT04019704
- Locations
- 🇺🇸
Clinical Research Site, Everett, Washington, United States
Maximizing Outcomes in Treating Acute Migraine
- Conditions
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 1594
- Registration Number
- NCT03896009
- Locations
- 🇺🇸
Clinical Research Site, Seattle, Washington, United States
Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03881852
- Locations
- 🇺🇸
CONCERT Study Site, San Antonio, Texas, United States
Assessing Symptomatic Clinical Episodes in Depression
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT03595579
- Locations
- 🇺🇸
Clinical Research Site, Bellevue, Washington, United States
Addressing Dementia Via Agitation-Centered Evaluation
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT03226522
- Locations
- 🇦🇺
Axsome study site, Caulfield, Melbourne, Victoria, Australia
🇺🇸Axsome Study Site, Everett, Washington, United States
A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 346
- Registration Number
- NCT02746068
- Locations
- 🇺🇸
Achieve Clinical Research, Birmingham, Alabama, United States
🇺🇸Accord Clinical Research, Port Orange, Florida, United States
🇺🇸Affinity Clinical Research Institute, Oak Lawn, Illinois, United States
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 312
- Registration Number
- NCT02741791
CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT02504008